Brabant G, Poll EM, Jonsson P, Polydorou D, Kreitschmann-Andermahr I. Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations?. Eur J Endocrinol. 2009 Nov. 161 suppl 1:S25-31. [QxMD MEDLINE Link]. [Full Text].
Tanriverdi F, Schneider HJ, Aimaretti G, Masel BE, Casanueva FF, Kelestimur F. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev. 2015 Jun. 36(3):305-42. [QxMD MEDLINE Link]. [Full Text].
Tanriverdi F, Kelestimur F. Neuroendocrine disturbances after brain damage: an important and often undiagnosed disorder. J Clin Med. 2015 Apr 28. 4(5):847-57. [QxMD MEDLINE Link]. [Full Text].
Guaraldi F, Grottoli S, Arvat E, Ghigo E. Hypothalamic-pituitary autoimmunity and traumatic brain injury. J Clin Med. 2015 May 19. 4(5):1025-35. [QxMD MEDLINE Link]. [Full Text].
Tanriverdi F, Kelestimur F. Classical and non-classical causes of GH deficiency in adults. Best Pract Res Clin Endocrinol Metab. 2017 Feb. 31(1):3-11. [QxMD MEDLINE Link].
Gola M, Bonadonna S, Doga M, Giustina A. Clinical review: growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab. 2005 Mar. 90(3):1864-70. [QxMD MEDLINE Link]. [Full Text].
Claessen KM, Appelman-Dijkstra NM, Adoptie DM, et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab. 2013 Jan. 98(1):352-61. [QxMD MEDLINE Link]. [Full Text].
Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2012 Jan. 166(1):13-20. [QxMD MEDLINE Link]. [Full Text].
Melmed S. Idiopathic adult growth hormone deficiency. J Clin Endocrinol Metab. 2013 Jun. 98(6):2187-97. [QxMD MEDLINE Link]. [Full Text].
Giuliano S, Talarico S, Bruno L, Nicoletti FB, Ceccotti C, Belfiore A. Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury. Endocrine. 2017 Oct. 58(1):115-23. [QxMD MEDLINE Link].
Kreber LA, Griesbach GS, Ashley MJ. Detection of growth hormone deficiency in adults with chronic traumatic brain injury. J Neurotrauma. 2016 Sep 1. 33(17):1607-13. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract. 2009 Sep-Oct. 15 suppl 2:1-29. [QxMD MEDLINE Link].
[Guideline] Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016 Feb. 174(2):P1-9. [QxMD MEDLINE Link]. [Full Text].
Stochholm K, Gravholt CH, Laursen T, et al. Incidence of GH deficiency - a nationwide study. Eur J Endocrinol. 2006 Jul. 155(1):61-71. [QxMD MEDLINE Link].
[Guideline] Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jun. 96(6):1587-609. [QxMD MEDLINE Link]. [Full Text].
Mo D, Blum WF, Rosilio M, Webb SM, Qi R, Strasburger CJ. Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study. J Clin Endocrinol Metab. 2014 Dec. 99(12):4581-8. [QxMD MEDLINE Link].
Gasco V, Caputo M, Lanfranco F, Ghigo E, Grottoli S. Management of GH treatment in adult GH deficiency. Best Pract Res Clin Endocrinol Metab. 2017 Feb. 31(1):13-24. [QxMD MEDLINE Link].
[Guideline] Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019 Nov. 25(11):1191-232. [QxMD MEDLINE Link]. [Full Text].
Hartman ML, Crowe BJ, Biller BM, et al, for the HyposCCS Advisory Board, US HypoCCS Study Group. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?. J Clin Endocrinol Metab. 2002 Feb. 87(2):477-85. [QxMD MEDLINE Link].
Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002 May. 87(5):2067-79. [QxMD MEDLINE Link].
Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab. 2003 Jan. 88(1):95-102. [QxMD MEDLINE Link].
US Food and Drug Administration. NDA approval [letter]. NDA 205598. Available at https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/205598Orig1s000ltr.pdf. December 20, 2017; Accessed: January 8, 2018.
Agrawal V, Garcia JM. The macimorelin-stimulated growth hormone test for adult growth hormone deficiency diagnosis. Expert Rev Mol Diagn. 2014 Jul. 14(6):647-54. [QxMD MEDLINE Link].
Garcia JM, Biller BMK, Korbonits M, et al. Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocr Connect. 2021 Jan. 10(1):76-83. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Yuen KC, Tritos NA, Samson SL, Hoffman AR, Katznelson L. American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the glucagon stimulation test in the diagnosis of adult growth hormone deficiency. Endocr Pract. 2016 Oct. 22(10):1235-44. [QxMD MEDLINE Link]. [Full Text].
Macrilen (macimorelin) [package insert]. Goettingen, Germany: Aeterna Zentaris GmbH. Revised January 2018. Available at [Full Text].
Arnold JR, Arnold DF, Marland A, Karavitaki N, Wass JA. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf). 2009 Mar. 70(3):435-8. [QxMD MEDLINE Link].
Buchfelder M, Kann PH, Wuster C, et al. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur J Endocrinol. 2007 Aug. 157(2):149-56. [QxMD MEDLINE Link].
Karavitaki N, Warner JT, Marland A, et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf). 2006 May. 64(5):556-60. [QxMD MEDLINE Link].
Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer?. Clin Endocrinol (Oxf). 2006 Feb. 64(2):115-21. [QxMD MEDLINE Link].
Poidvin A, Carel JC, Ecosse E, Levy D, Michon J, Coste J. Increased risk of bone tumors after growth hormone treatment in childhood: A population-based cohort study in France. Cancer Med. 2018 Jun 14. 7(7):3465-73. [QxMD MEDLINE Link]. [Full Text].
Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML, et al. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab. 2004 Jul. 89(7):3224-33. [QxMD MEDLINE Link].
Blum WF, Alherbish A, Alsagheir A, et al. The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr Connect. 2018 Jun. 7(6):R212-R222. [QxMD MEDLINE Link]. [Full Text].
Johannsson G, Gordon MB, Hojby Rasmussen M, et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020 Apr 1. 105(4):e1358–e1376. [QxMD MEDLINE Link]. [Full Text].
Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations - current status and future considerations. J Clin Endocrinol Metab. 2020 Jun 1. 105(6):e2121-e2133. [QxMD MEDLINE Link]. [Full Text].
Giannoulis MG, Sonksen PH, Umpleby M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2006 Feb. 91(2):477-84. [QxMD MEDLINE Link].
Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999 Nov. 84(11):3956-60. [QxMD MEDLINE Link].
Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement?. Clin Endocrinol (Oxf). 1995 Aug. 43(2):143-9. [QxMD MEDLINE Link].
Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004 May. 89(5):2192-9. [QxMD MEDLINE Link].
Losa M, Scavini M, Gatti E, et al. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid. 2008 Dec. 18(12):1249-54. [QxMD MEDLINE Link].
Giavoli C, Libe R, Corbetta S, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab. 2004 Nov. 89(11):5397-401. [QxMD MEDLINE Link].
Moock J, Albrecht C, Friedrich N, et al. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the study of health in Pomerania. Eur J Endocrinol. 2009 Jan. 160(1):17-24. [QxMD MEDLINE Link]. [Full Text].
Holmes SJ, McKenna SP, Doward LC, Hunt SM, Shalet SM. Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency. Endocrinol Metab. 1995 Jan 1. 2(1):63-9.
Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 1992 Nov. 37(5):387-97. [QxMD MEDLINE Link].
Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab. 2004 Apr. 89(4):1684-93. [QxMD MEDLINE Link].
Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004 Jul. 89(7):3306-12. [QxMD MEDLINE Link].
Chikani V, Cuneo RC, Hickman I, Ho KK. Growth hormone (GH) enhances anaerobic capacity: impact on physical function and quality of life in adults with GH deficiency. Clin Endocrinol (Oxf). 2016 Oct. 85(4):660-8. [QxMD MEDLINE Link].
van Bunderen CC, van Varsseveld NC, Erfurth EM, Ket JC, Drent ML. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol (Oxf). 2014 Jul. 81(1):1-14. [QxMD MEDLINE Link].
De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab. 1992 Sep. 75(3):833-7. [QxMD MEDLINE Link].
Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update. J Clin Endocrinol Metab. 2014 Jan. 99(1):18-29. [QxMD MEDLINE Link].
Cannavo S, Marini F, Curto L, et al. High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency. J Endocrinol Invest. 2011 Jan. 34(1):32-7. [QxMD MEDLINE Link].
Castillo AR, Zantut-Wittmann DE, Neto AM, Jales RM, Garmes HM. Panhypopituitarism without GH replacement: about insulin sensitivity, CRP levels, and metabolic syndrome. Horm Metab Res. 2018 Sep. 50(9):690-5. [QxMD MEDLINE Link]. [Full Text].
Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol. 2006 Apr. 154(4):537-43. [QxMD MEDLINE Link]. [Full Text].
Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990 Aug 4. 336(8710):285-8. [QxMD MEDLINE Link].
Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation. 2003 Nov 25. 108(21):2648-52. [QxMD MEDLINE Link].
Colao A, Di Somma C, Spiezia S, et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab. 2008 Sep. 93(9):3416-24. [QxMD MEDLINE Link].
Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol. 2006 Jul. 155(1):79-90. [QxMD MEDLINE Link]. [Full Text].
Elbornsson M, Gotherstrom G, Boaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013 May. 168(5):745-53. [QxMD MEDLINE Link]. [Full Text].
Colao A, Di Somma C, Rota F, et al. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab. 2005 Apr. 90(4):2056-62. [QxMD MEDLINE Link].
Jorgensen JOL, Juul A. Therapy of endocrine disease: growth hormone replacement therapy in adults: 30 years of personal clinical experience. Eur J Endocrinol. 2018 Jul. 179(1):R47-56. [QxMD MEDLINE Link].
Verhelst J, Mattsson AF, Camacho-Hubner C, Luger A, Abs R. The prevalence of the metabolic syndrome and associated cardiovascular complications in adult-onset GHD during GH replacement: a KIMS analysis. Endocr Connect. 2018 May. 7(5):653-62. [QxMD MEDLINE Link].
Appelman-Dijkstra NM, Claessen KM, Hamdy NA, Pereira AM, Biermasz NR. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf). 2014 Nov. 81(5):727-35. [QxMD MEDLINE Link].
Wuster C, Abs R, Bengtsson BA, et al, for the KIMS Study Group and the KIMS International Board, Pharmacia Upjohn International Metabolic Database. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001 Feb. 16(2):398-405. [QxMD MEDLINE Link].
Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 1994 Mar. 78(3):669-74. [QxMD MEDLINE Link].
Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993 Sep. 129(3):201-6. [QxMD MEDLINE Link].
Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 1997 Sep. 137(3):240-5. [QxMD MEDLINE Link].
Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res. 2002 Jun. 17(6):1081-94. [QxMD MEDLINE Link].
Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab. 2014 Mar. 99(3):852-60. [QxMD MEDLINE Link]. [Full Text].
Drake WM, Rodriguez-Arnao J, Weaver JU, et al. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol (Oxf). 2001 Apr. 54(4):525-32. [QxMD MEDLINE Link].
Snyder PJ, Biller BM, Zagar A, et al. Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res. 2007 May. 22(5):762-70. [QxMD MEDLINE Link].
Beshyah SA, Freemantle C, Thomas E, et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf). 1995 Feb. 42(2):179-89. [QxMD MEDLINE Link].
Maiter D, Abs R, Johannsson G, et al. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur J Endocrinol. 2006 Aug. 155(2):253-60. [QxMD MEDLINE Link]. [Full Text].
Attanasio AF, Bates PC, Ho KK, et al, for the Hypoptiuitary Control and Complications Study International Advisory Board. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database. J Clin Endocrinol Metab. 2002 Apr. 87(4):1600-6. [QxMD MEDLINE Link]. [Full Text].
Elgzyri T, Castenfors J, Hagg E, Backman C, Thoren M, Bramnert M. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency. Clin Endocrinol (Oxf). 2004 Jul. 61(1):113-22. [QxMD MEDLINE Link].
Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab. 2008 Nov. 93(11):4413-7. [QxMD MEDLINE Link]. [Full Text].
Hartman ML, Weltman A, Zagar A, Qualy RL, Hoffman AR, Merriam GR. Growth hormone replacement therapy in adults with growth hormone deficiency improves maximal oxygen consumption independently of dosing regimen or physical activity. J Clin Endocrinol Metab. 2008 Jan. 93(1):125-30. [QxMD MEDLINE Link]. [Full Text].
Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G, Svensson J. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 2009 Mar. 94(3):809-16. [QxMD MEDLINE Link]. [Full Text].
Cenci MC, Soares DV, Spina LD, et al. Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary. 2009. 12(4):322-9. [QxMD MEDLINE Link].
Gonzalez S, Sathyapalan T, Javed Z, Atkin SL. Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency. Front Endocrinol (Lausanne). 2018. 9:56. [QxMD MEDLINE Link]. [Full Text].
Thilmany S, Mchirgui L, Brunelle C, Beauloye V, Maiter D, Alexopoulou O. Correlation between the responses to growth hormone (GH) treatment during childhood and adulthood in a monocentric cohort of GH-deficient patients. Horm Metab Res. 2018 Jun. 50(6):462-8. [QxMD MEDLINE Link].
Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009 Apr. 30(2):152-77. [QxMD MEDLINE Link]. [Full Text].
Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017 Sep. 22(3):145-52. [QxMD MEDLINE Link]. [Full Text].
Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf). 1994 Jan. 40(1):111-6. [QxMD MEDLINE Link].
Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab. 1996 Mar. 81(3):1169-72. [QxMD MEDLINE Link].
Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010 Jun. 31(3):301-42. [QxMD MEDLINE Link].
Lindholm J, Nielsen EH, Bjerre P, et al. Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol (Oxf). 2006 Jul. 65(1):51-8. [QxMD MEDLINE Link].
Stochholm K, Gravholt CH, Laursen T, et al. Mortality and GH deficiency: a nationwide study. Eur J Endocrinol. 2007 Jul. 157(1):9-18. [QxMD MEDLINE Link]. [Full Text].
Nielsen EH, Lindholm J, Laurberg P. Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf). 2007 Nov. 67(5):693-7. [QxMD MEDLINE Link].
Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN. Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab. 2015 Apr. 100(4):1405-11. [QxMD MEDLINE Link].
Koltowska-Haggstrom M, Mattsson AF, Shalet SM. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol. 2009 Nov. 161(suppl 1):S51-64. [QxMD MEDLINE Link]. [Full Text].
Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf). 2002 Sep. 57(3):363-70. [QxMD MEDLINE Link].
Appelman-Dijkstra NM, Claessen KM, Roelfsema F, Pereira AM, Biermasz NR. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol. 2013 Jul. 169(1):R1-14. [QxMD MEDLINE Link]. [Full Text].
Garcia JM, Biller BMK, Korbonits M, et al. Macimorelin as a diagnostic test for adult growth hormone deficiency. J Clin Endocrinol Metab. 2018 Aug 1. 103(8):3083-93. [QxMD MEDLINE Link]. [Full Text].
Brod M, Hojbjerre L, Adalsteinsson JE, Rasmussen MH. Assessing the impact of growth hormone deficiency and treatment in adults: development of a new disease-specific measure. J Clin Endocrinol Metab. 2014 Apr. 99(4):1204-12. [QxMD MEDLINE Link]. [Full Text].
McCallum RW, Petrie JR, Dominiczak AF, Connell JM. Growth hormone deficiency and vascular risk. Clin Endocrinol (Oxf). 2002 Jul. 57(1):11-24. [QxMD MEDLINE Link].
Mavromati M, Kuhn E, Agostini H, et al. Classification of patients with GH disorders may vary according to the IGF-I assay. J Clin Endocrinol Metab. 2017 Aug 1. 102(8):2844-52. [QxMD MEDLINE Link].
[Guideline] Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 Nov. 101(11):3888-921. [QxMD MEDLINE Link]. [Full Text].
Ramos-Levi AM, Marazuela M. Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls. Endocrine. 2018 May. 60(2):203-18. [QxMD MEDLINE Link].
Johannsson G, Feldt-Rasmussen U, Hakonsson IH, et al, for the REAL 2 Study Group. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. 2018 May. 178(5):491-9. [QxMD MEDLINE Link].
Brod M, Beck JF, Hojbjerre L, et al. Assessing the impact of growth hormone deficiency (GHD) in adults: interpreting change of the treatment-related impact measure-adult growth hormone deficiency (TRIM-AGHD). Pharmacoecon Open. 2019 Mar. 3(1):71-80. [QxMD MEDLINE Link]. [Full Text].